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OBJECTIVES This study was conducted to assess the safety and effectiveness of cardiac resynchronization
therapy (CRT) when combined with an implantable cardioverter defibrillator (ICD).
BACKGROUND Long-term outcome of CRT was measured in patients with symptomatic heart failure (HF),
intraventricular conduction delay, and malignant ventricular tachyarrhythmias (ventricular
tachycardia/ventricular fibrillation [VT/VF]) requiring therapy from an ICD.
METHODS Patients (n  490) were implanted with a device capable of providing both CRT and ICD
therapy and randomized to CRT (n  245) or control (no CRT, n  245) for up to six
months. The primary end point was progression of HF, defined as all-cause mortality,
hospitalization for HF, and VT/VF requiring device intervention. Secondary end points
included peak oxygen consumption (VO2), 6-min walk (6 MW), New York Heart
Association (NYHA) class, quality of life (QOL), and echocardiographic analysis.
RESULTS A 15% reduction in HF progression was observed, but this was statistically insignificant (p 
0.35). The CRT, however, significantly improved peak VO2 (0.8 ml/kg/min vs. 0.0
ml/kg/min, p  0.030) and 6 MW (35 m vs. 15 m, p  0.043). Changes in NYHA class (p
 0.10) and QOL (p  0.40) were not statistically significant. The CRT demonstrated
significant reductions in ventricular dimensions (left ventricular internal diameter in diastole
3.4 mm vs.0.3 mm, p 0.001 and left ventricular internal diameter in systole4.0
mm vs. 0.7 mm, p  0.001) and improvement in left ventricular ejection fraction (5.1% vs.
2.8%, p  0.020). A subgroup of patients with advanced HF (NYHA class III/IV)
consistently demonstrated improvement across all functional status end points.
CONCLUSIONS The CRT improved functional status in patients indicated for an ICD who also have
symptomatic HF and intraventricular conduction delay. (J Am Coll Cardiol 2003;42:
1454–9) © 2003 by the American College of Cardiology Foundation
Heart failure (HF) is a syndrome that affects an estimated
five million Americans, with 400,000 to 700,000 new cases
annually (1). Frequently, life-threatening ventricular ar-
rhythmias may also accompany this condition (2). Heart
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failure may be compounded in patients with intraventricular
conduction delay possibly due to a loss of ventricular synchrony
(3). It has been hypothesized that biventricular cardiac stimu-
lation could improve hemodynamics by resynchronizing the
ventricles in patients with intraventricular conduction delays
(4). To distinguish between pacing therapy for traditional
indications and specific therapy for HF, the term “cardiac
resynchronization therapy” (CRT) will be used to describe the
therapy provided by these implanted systems.
Published studies suggest that short-term improvements
in hemodynamics (5,6) and long-term improvements in
functional status are possible with CRT (7–9). Previously
published studies have been restricted to patients with
symptomatic HF but without conventional indications for an
implantable cardioverter defibrillator (ICD) or had relatively
small sample sizes and lacked a concurrent control group. This
study is the first to describe the results of CRT in a double-
blind, randomized controlled study in patients with both
symptomatic HF and ventricular tachyarrhythmias.
METHODS
Study design. Major entry criteria for participation in the
study include New York Heart Association (NYHA) class
II to IV, left ventricular ejection fraction (LVEF) 35%,
QRS interval 120 ms, and conventional indications for
implant of an ICD. Patients could not be enrolled if they
had atrial tachyarrhythmias or conventional indications for a
permanent pacemaker. The full eligibility criteria have been
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previously described (10). Because of the immediate need
for ICD therapy, investigators implanted the system first
and then programmed the randomized therapy after a
minimum 30-day period with no CRT. During this period,
investigators were permitted to optimize pharmacologic
therapy before initiating the randomized therapy. This step
was added to reduce bias so that the observed changes could
be attributed to CRT rather than changes in background
medical therapy. The original study design (Phase I) was a
crossover design with two three-month observation periods;
its design and end point metrics of peak oxygen consump-
tion (VO2), 6-min walk (6 MW) distance, and quality of life
(QOL) using the Minnesota Living with Heart Failure
Questionnaire have been previously described (10).
The study design was later modified (Phase II) due to
regulatory concerns over morbidity and mortality associated
with CRT and the length of follow-up in the randomized
mode. However, no changes were made to the study’s eligibil-
ity criteria. Both designs are shown in Figure 1. The sponsor
elected to change the primary end point from peak VO2 to a
composite end point driven by events associated with worsen-
ing HF, and the study was changed from a crossover to a
parallel design. A Heart Failure Events Committee (HFEC)
adjudicated all deaths and hospitalizations.
Device description. The implanted system consisted of a
pulse generator capable of providing both CRT and ICD
therapy (Model 1822 Ventak CHF Automatic Implantable
Cardioverter Defibrillator or Model 1823 Contak CD
device, Guidant Corporation, St. Paul, Minnesota). Ini-
tially, the left ventricle (LV) was paced with a commercially
available epicardial pace/sense lead (Model 4965 CapSure
Epi pace/sense lead, Medtronic Corporation, Minneapolis,
Minnesota). A lead (Model 4510/4511/4512/4513 Easytrak
coronary venous pace/sense lead, Guidant Corporation, St.
Paul, Minnesota) that could be placed transvenously under
fluoroscopic guidance using over-the-wire techniques in the
coronary venous vasculature was later introduced. A cardio-
version/defibrillation lead (Model 0125 Endotak lead,
Guidant Corporation, St. Paul, Minnesota) was implanted
in the right ventricle, and a pace/sense lead was placed in the
right atrium for this three-lead CRT system.
Statistical methods. The primary end point was progres-
sion of HF, defined as a composite of all-cause mortality,
hospitalization for worsening HF, and ventricular tachyar-
rhythmias requiring device therapy. It was postulated that
the therapy would reduce the overall incidence of these
events by 25%. The primary end point was analyzed such
that patients in Phase I contributed data from a three-
month treatment phase and patients in Phase II contributed
data from a six-month treatment phase. Cox proportional
hazard models were fit for the combination of events with
the treatment effect adjusted for covariates chosen by the
HFEC before primary end point analysis. These covariates
included NYHA class, QRS interval, ischemic etiology,
LVEF, and bundle-branch morphology. The Wei method
was used to calculate a composite effect of the treatment and
covariates (11).
The longitudinal (repeated measures) analysis method
was performed on continuous variables to compare the
difference in the sample means. This method accounted for
the patterns of missing data, took full advantage of the
correlation structure, and used all the data to estimate the
model parameters (12). Model parameters were estimated
using maximum likelihood (SAS/STAT Version 8.1, SAS
Institute, Inc., Cary, North Carolina). Values of p  0.05
were considered to be significant for all tests.
RESULTS
Patient disposition. A total of 581 patients were enrolled
at 47 investigational centers in the U.S. from February 1998
through December 2000. All patients enrolled provided writ-
ten informed consent approved by each participating center’s
Institutional Review Board, and procedures were conducted in
accordance with each participating investigator’s institutional
guidelines. All patients were indicated for implantation of an
ICD in accordance with American College of Cardiology/
American Heart Association guidelines (13).
Of the 581 patients enrolled in the study, 14 patients
Abbreviations and Acronyms
CRT  cardiac resynchronization therapy
HF  heart failure
HFEC  Heart Failure Events Committee
ICD  implantable cardioverter defibrillator
LV  left ventricle/left ventricular
LVEF  left ventricular ejection fraction
LVIDd  left ventricular internal diameter in diastole
LVIDs  left ventricular internal diameter in systole
NYHA New York Heart Association classification
QOL  quality of life
VO2  oxygen consumption
VT/VF ventricular tachycardia/ventricular fibrillation
6 MW  6-min walk
Figure 1. Study design for each phase. Phase I (top) was a crossover design
(n  248); Phase II (bottom) was a parallel design (n  333). CRT 
cardiac resynchronization therapy; Rand  randomization time.
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either withdrew informed consent or were determined not
to meet eligibility criteria and were withdrawn by the
investigator before an implant procedure. Another 66 pa-
tients did not receive an investigational system because of
the inability to place the coronary venous lead; they received
a conventional ICD system instead. Thus, 501 patients were
implanted with the investigational system, with 448 (89%)
receiving a transvenous system and 53 (11%) receiving a
transthoracic system.
Of the transvenous leads, 242 (54%) were in a lateral vein,
142 (32%) were in an anterior vein, and 59 (13%) were
posterior. Lead location was not recorded for the remaining
five patients (1%). Of the leads placed transthoracically, 24
(45%) were placed apically, 14 (26%) were placed lateral, 11
(21%) were placed anterior, and 4 (8%) were implanted in a
posterior position. Of the patients implanted, 222 were
enrolled in Phase I (51 patients receiving transthoracic
leads) and 279 were enrolled in Phase II (two patients
receiving transthoracic leads).
Ten patients died and one withdrew within the 30-day
post-implant recovery period before the randomized therapy
could be programmed, leaving 490 patients available for
analysis. Two of the 10 deaths were perioperative, with one
death attributed to pulseless electrical activity resulting from
defibrillation threshold testing and the other due to incessant
ventricular tachycardia (VT) during the implant procedure. Of
the remaining eight deaths, five were due to pump failure, two
were attributed to cardiac causes unrelated to pump failure, and
one was due to unknown cause as adjudicated by the HFEC.
None of the latter eight deaths were attributed to the implant
procedure. Patient demographics at the time of implant are
reported in Table 1. The two randomized groups were
balanced with no statistically significant differences with
respect to baseline characteristics.
Influence of post-implant recovery period. All patients
were in NYHA class II to IV at the time of entry into the
study. During the post-implant recovery period, investiga-
tors were permitted to adjust or initiate HF medications to
stabilize the patients’ condition before implementing the
randomized therapy. Many patients demonstrated signifi-
cant symptomatic improvement with medical therapy dur-
ing this period. Of the 328 patients who presented in
NYHA class III/IV, 131 (40%) improved to NYHA class I
or II, whereas 30 of 162 (19%) NYHA class II patients
worsened to NYHA class III/IV during this period. Thus,
after investigators had the opportunity to optimize medical
therapy, 227 patients were in NYHA class III/IV and 263
were in NYHA class I/II before the office visit in which the
randomized therapy was initiated.
Baseline predictors of improvement. Significant interac-
tions of the five covariates chosen by the HFEC were found
with the secondary end points (Table 2) as part of a post hoc
analysis, but no interactions were found with the primary
end point. The NYHA class, measured at the time of the
randomization visit, was found to be the most consistent
predictor of improvement with CRT across the functional
status end points. Demographics for the NYHA class III/IV
Table 1. Baseline Characteristics
Characteristics
CRT
(n  245)
No CRT
(n  245)
Age (yrs) 66  11 66  11
Gender (male, %) 85 83
NYHA class (II/III/IV, %) 32/60/8 33/57/10
QRS interval (ms) 160  27 156  26
IVCD (LBBB/NS/RBBB, %) 54/32/14 55/33/12
Etiology (ischemic, %) 67 71
Diuretic (%) 88 83
ACE inhibitor/ARB (%) 86 89
Beta-blocker (%) 48 46
Digoxin (%) 69 68
Peak VO2 (ml/kg/min) 13.8  4.6 13.5  3.8
QOL (points) 44  25 40  23
6 MW (m) 316  119 320  121
LVIDd (mm) 71  11 70  10
LVIDs (mm) 59  11 58  11
LVEF (%) 21  7 22  7
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CRT
 cardiac resynchronization therapy; IVCD  intraventricular conduction delay;
LBBB left bundle-branch block; LVEF left ventricular ejection fraction; LVIDd
 left ventricular internal diameter in diastole; LVIDs  left ventricular internal
diameter in systole; NS  non-specific; NYHA  New York Heart Association;
QOL  quality of life; RBBB  right bundle-branch block; VO2  oxygen
consumption; 6 MW  6-min walk.
Table 2. Interaction Table for Functional Status by Covariate
Covariate Peak VO2 QOL 6 MW NYHA Class
NYHA class III/IV    
Wider QRS width   — 
LBBB/NSIVCD
morphology
 — — 
Non-ischemic etiology —  — —
Lower LVEF  — — —
 Significant interaction (p 0.05);  trend to significance (0.05 p 0.10);
—  no significant interaction (p  0.10).
NSIVCD non-specific intraventricular conduction delay. Other abbreviations as
in Table 1.
Table 3. Baseline Characteristics (NYHA Class III/IV
Post-Implant Recovery)
Characteristic
CRT
(n  117)
No CRT
(n  110)
Age (yrs) 66  11 66  11
Gender (male, %) 77 78
NYHA class (II/III/IV, %) 17/73/10 10/71/19
QRS interval (ms) 164  27 152  26
IVCD (LBBB/NS/RBBB, %) 50/32/18 54/34/12
Etiology (ischemic, %) 65 71
Diuretic (%) 92 86
ACE inhibitor/ARB (%) 81 89
Beta-blocker (%) 45 40
Digoxin (%) 72 68
Peak VO2 (ml/kg/min) 12.0  3.8 12.1  3.4
QOL (points) 56  22 49  21
6 MW (m) 268  123 269  117
LVIDd (mm) 73  11 70  10
LVIDs (mm) 61  11 58  11
LVEF (%) 21  6 21  6
Abbreviations as in Table 1.
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patient population are presented in Table 3. Results for all
patients are presented in Table 4 and are stratified by
NYHA class I/II and NYHA class III/IV at the conclusion
of the post-implant recovery period.
Progression of HF. Of the 245 patients randomized to
CRT, a total of 79 events were observed, comprised of 11
deaths, 32 patients with at least one HF hospitalization, and
36 patients with at least one ventricular tachycardia/
ventricular fibrillation (VT/VF) event. This result is com-
pared with 94 events (16 deaths, 39 patients with at least
one HF hospitalization, and 39 patients with at least one
VT/VF event) observed in 245 patients randomized to no
CRT. Relative reductions that were favorable to CRT were
seen in all components. However, the overall relative reduc-
tion in composite HF progression of 15% with CRT was
not statistically significant (p  0.35). No statistically
significant reductions were found when stratified into
NYHA class I/II (12% reduction) or NYHA class III/IV
(22% reduction). Kaplan-Meier curves illustrating time to
event for both all-cause mortality and all-cause mortality
plus HF hospitalization are shown in Figure 2.
Peak VO2, 6 MW, QOL, and NYHA class. In the
all-patients group (Table 4), CRT significantly improved
peak oxygen consumption (p  0.030) and 6MW distance
(p  0.043). The improvement in NYHA class did not
achieve statistical significance (p  0.10). The QOL im-
proved more in those patients randomized to CRT than in
patients randomized to control, but this change did not
achieve statistical significance (p  0.39).
Patients with NYHA class III/IV demonstrated improve-
ment in peak VO2 (p  0.003), 6 MW distance (p 
0.029), NYHA class (p  0.006), and QOL (p  0.017).
Patients with NYHA class I/II showed no significant
improvement in any of these parameters.
Table 4. Selected Secondary End Point Outcomes
End Point
All Patients
NYHA Class III/IV
at Randomization
NYHA Class I/II
at Randomization
CRT No CRT p Value CRT No CRT p Value CRT No CRT p Value
Peak VO2 (ml/kg/min) 0.8  0.3 0.0  0.3 0.030 1.8  0.4 0.0  0.4 0.003 0.2  0.3 0.0  0.3 0.77
(n  216) (n  201) (n  96) (n  80) (n  120) (n  121)
6 MW (m) 35  7 15  7 0.043 60  12 21  13 0.029 17  9 10  9 0.55
(n  224) (n  220) (n  99) (n  90) (n  125) (n  130)
QOL (points) 7  2 5  2 0.39 16  3 5  3 0.017 1  2 4  2 0.26
(n  234) (n  225) (n  107) (n  96) (n  127) (n  129)
NYHA class (%) (n  109) (n  116) (n  45) (n  48) (n  64) (n  68)
Improved 2 classes 11 2 27 4 — —
Improved 1 class 25 30 0.10 47 50 0.006 9 16 0.84
No change 51 51 22 38 72 60
Worsened 13 17 4 8 19 24
LVIDd (mm) 3.4  0.6 0.3  0.6  0.001 4.9  1.0 0.2  1.1 0.001 2.4  0.8 0.0  0.8 0.024
(n  228) (n  219) (n  104) (n  102) (n  124) (n  117)
LVIDs (mm) 4.0  0.7 0.7  0.7  0.001 5.4  1.1 0.6  1.1 0.002 3.2  0.8 0.5  0.8 0.014
(n  228) (n  219) (n  104) (n  102) (n  124) (n  117)
LVEF (%) 5.1  0.7 2.8  0.7 0.020 6.0  1.1 2.3  1.2 0.029 4.7  0.9 2.9  0.9 0.16
(n  222) (n  216) (n  99) (n  91) (n  123) (n  125)
Abbreviations as in Table 1.
Figure 2. Kaplan-Meier curves for all-cause mortality (left) and all-cause mortality and heart failure (HF) hospitalization (right). CRT  cardiac
resynchronization therapy.
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Echocardiographic data. Cardiac resynchronization ther-
apy was associated with significant decreases in LV dimen-
sions in the all-patients group. The LVIDd was significantly
improved (p  0.001) as was left ventricular internal
diameter in systole (LVIDs) (p  0.001). The LVEF also
significantly increased with CRT (p  0.020). Decreases in
LV dimensions were also noted in NYHA class III/IV
patients with CRT in left ventricular internal diameter in
diastole (LVIDd) (p  0.001), LVIDs (p  0.002), and
LVEF (p  0.029). Patients in NYHA class I/II demon-
strated significant reductions in LVIDd (p  0.024) and in
LVIDs (p  0.014) with CRT.
All-cause mortality. A total of 109 deaths were reported
throughout the study (27 deaths during the study treatment
phase and 70 deaths during the long-term follow-up phase)
and were adjudicated by an independent events committee.
Of the 109 deaths, 47 (43%) were due to pump failure, 21
(19%) were non-cardiac, 9 (8%) were arrhythmic, 2 (2%)
were ischemic, and 2 (2%) were cardiac in nature but of
unknown etiology. The remaining 28 (26%) deaths had
insufficient documentation for the committee to adjudicate
cause of death. Operative mortality, defined as death from
any cause within 30 days of the implant procedure, ac-
counted for 12/567 (2%) of patients who underwent the
implant procedure. Total survival at one, two, and three
years was 85%, 74%, and 70%, respectively.
Spontaneous ventricular tachyarrhythmias. There was no
statistically significant difference in the incidence or fre-
quency of ventricular tachyarrhythmias when comparing
CRT with no CRT. Of the 245 patients programmed to
CRT, 36 (15%) received appropriate treatment of ventricular
tachyarrhythmias with 25 (10%) having VT alone, 7 (3%)
having VF alone, and 4 (2%) having both VT and VF. Of the
245 patients programmed to no CRT, 39 (16%) received
appropriate device therapy. Ventricular tachycardia alone was
reported in 27 (11%) patients, VF alone in 6 (2%) patients, and
both VT and VF in 6 (2%) patients.
When excluding patients who had no VT/VF episodes,
those patients randomized to CRT had a median of 2.5
episodes while those randomized to no CRT had a median
of 2 episodes during the therapy evaluation phase. The
device delivered antitachycardia pacing in a biventricular
fashion. Spontaneous monomorphic VT was successfully
treated with biventricular antitachycardia pacing in 927 of
1,053 (88%) episodes.
DISCUSSION
Progression of HF. The present study is the first report of
CRT with an ICD in a double-blind, randomized, clinical
study in a patient population with an ICD indication and
symptomatic HF and intraventricular conduction delay.
Although relative improvements in HF progression were
observed that were favorable towards CRT, the magnitude
of improvement was not statistically significant.
The primary end point analysis was based on an expected
rate of HF events. The study was not adequately powered to
detect a statistically significant difference because the actual
event rate observed was approximately half that expected in
the original study design. In addition to the relatively brief
follow-up period of three months for Phase I patients, the
widespread adoption of HF medications, such as beta-
blockers and spironolactone, after the publication of positive
clinical trial results and an evolution in HF management
that focused on increased outpatient surveillance may have
contributed to the reduction in expected events. Many
patients responded positively once medical management
was optimized before randomization. This improvement in
status made it more difficult to show benefit in healthier
patients while reducing the statistical power to show im-
provement in those who remained in NYHA class III/IV
despite optimizing HF medications.
Secondary end points. Although this study was negative in
terms of its primary end point, several important findings
were observed about functional capacity, QOL, and reverse
remodeling. Peak VO2, which was the primary end point of
the original study design, and 6 MW distance both dem-
onstrated statistically significant improvements. Although
angiotensin-converting enzyme inhibitors and beta-blockers
have been proven to reduce mortality and hospitalization,
these agents generally do not improve exercise tolerance
(14–16). Thus, CRT appears to complement existing phar-
macologic therapy by improving functional status without
evidence for increased morbidity or mortality.
Echocardiographic analysis also revealed a statistically
significant improvement in LV dimensions and LVEF.
These findings are important because they provide evidence
for reversal of the remodeling effects of HF. Interestingly,
significant reductions in LV dimensions were noted in
NYHA class I/II patients. Future studies may demonstrate
benefit in patients with dyssynchrony but without overt
symptoms by preventing remodeling.
Comparison with other studies. The results of two other
studies, Multisite Insync Randomized Clinical Evaluation
(MIRACLE) and InSync ICD (also referred to as “MIR-
ACLE ICD”), have recently been publicized (17,18). These
two studies enrolled patients with intraventricular conduc-
tion delay, LV dysfunction, and symptomatic HF while on
stable HF medications. Patients without an ICD indication
were enrolled in MIRACLE; those with an ICD indication
were enrolled in InSync ICD.
The studies were similar in that CRT consisted of
biventricular stimulation with LV stimulation from a lead
placed in the coronary venous vasculature. All three designs
called for patients to be randomized to CRT or no CRT for
a six-month period, and all used similar methods for
quantifying changes in functional status (peak VO2, 6 MW,
QOL, NYHA class, and echocardiography).
Dissimilarities in the studies were related to the patient
populations (NYHA class II to IV in Contak CD and
InSync ICD vs. NYHA class III to IV in MIRACLE) and
how baseline testing was performed. Patients in the ad-
vanced HF subgroup of the Contak CD study most closely
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correspond to the patient population in MIRACLE and the
NYHA class III/IV subgroup of patients in InSync ICD for
whom results were reported. In Contak CD, baseline testing
was performed post-implant after a minimum 30-day wait-
ing period, whereas the other two studies had most baseline
tests performed pre-implant. Finally, the major difference in
the studies was the use of mortality, hospitalization, and
VT/VF events as the primary end point in the Contak CD
study, whereas the MIRACLE and InSync ICD studies
selected 6 MW, NYHA class, and QOL as co-primary end
points.
All three studies showed directional improvement in
mortality with CRT, but none achieved statistical signifi-
cance or were powered to detect a difference. Similarly, all
three studies demonstrated that CRT was safe. Improve-
ments in functional capacity were highly consistent among
the functional status end points when comparing the ad-
vanced HF subgroup with the results from the other two
studies. Thus, the results of the published studies are highly
concordant in demonstrating the safety and effectiveness of
CRT across trials with similar patient populations.
Study limitations. Patients were studied in a randomized
mode for only six months, with some patients followed for
only three months. Ongoing studies with longer follow-up
intervals, such as the Comparison of Medical Therapy,
Pacing, and Defibrillation in Chronic Heart Failure
(COMPANION) and CArdiac REsynchronization in
Heart Failure (CARE-HF) studies, are expected to deter-
mine long-term benefit (19,20). Applicability to patients
with arrhythmias besides VT/VF is not well known, and it
is unknown if the results can be generalized to patients with
chronic atrial fibrillation, chronotropic incompetence, and
sinus bradycardia. Furthermore, CRT was delivered in an
atrial synchronous manner (i.e., VDD mode). The effects of
atrial pacing as well as adaptive-rate pacing delivered with
the DDD(R) modes were not studied.
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